In Thursday’s Wall Street session, Regenxbio Inc (NASDAQ:RGNX) shares traded at $8.74, up 1.39% from the previous session.
RGNX stock price is now -2.87% away from the 50-day moving average and 1.63% away from the 200-day moving average. The market capitalization of the company currently stands at $440.40M.
With the price target reduced from $38 to $14, Goldman Downgraded its rating from Buy to Neutral for Regenxbio Inc (NASDAQ: RGNX). , while ‘Morgan Stanley’ rates the stock as ‘Overweight’
In other news, Mills Kenneth T., Director sold 20,602 shares of the company’s stock on May 12 ’25. The stock was sold for $163,046 at an average price of $7.91. Upon completion of the transaction, the Director now directly owns 475,103 shares in the company, valued at $4.15 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 12 ’25, Director KENNETH MILLS bought 20,602 shares of the business’s stock. A total of $154,927 was incurred on buying the stock at an average price of $7.52. A total of 9.39% of the company’s stock is owned by insiders.
During the past 12 months, Regenxbio Inc has had a low of $5.03 and a high of $15.36. As of last week, the company has a debt-to-equity ratio of 0.49, a current ratio of 2.93, and a quick ratio of 2.93. The fifty day moving average price for RGNX is $8.9978 and a two-hundred day moving average price translates $8.5994 for the stock.
The latest earnings results from Regenxbio Inc (NASDAQ: RGNX) was released for 2025-03-31. The net profit margin was -100.62% and return on equity was -47.44% for RGNX. The company reported revenue of $89.01 million for the quarter, compared to $15.62 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 469.79 percent. For the current quarter, analysts expect RGNX to generate $40.87M in revenue.
